The future of two chemical abortion drugs hangs in the balance. Attorneys general from 44 states square off over the FDA’s approval of a mail order pill. The U.S. military and NORAD shot down three unidentified flying objects over Canada over the weekend. Various lawmakers are now demanding more insight into what exactly happened. In…

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said…

Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. Pfizer Analysts SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased…

Pfizer Inc. said on Wednesday it will provide an additional 2.5 million doses of its COVID-19 pill Paxlovid to the United Kingdom. A total of 2.75 million doses of the pill are expected to be delivered to the UK through 2022, the drugmaker said.

The European Union’s drug regulator on Friday advised that an experimental COVID-19 pill from Merck should be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of their disease worsening. The European Medicines Agency (EMA) said the pill, developed along with Ridgeback Biotherapeutics, should…

U.S. government officials have reached an agreement with Pfizer that secures 10 million courses of the drugmaker’s COVID-19 pill. The government is paying $5.3 billion, or $529 a course for the pill. The price is due to the “high committed volume of treatment courses being purchased through 2022,” with similar agreements reached with several other…

Pfizer on Tuesday said it submitted a request for emergency clearance for a pill designed to treat COVID-19. The treatment, known as Paxlovid, is meant to keep COVID-19 patients with mild or moderate symptoms out of hospitals. It reduced the risk of hospitalization or death in a clinical trial, according to an interim analysis the…

Pfizer and a United Nations-backed group announced Monday that the drugmaker would let outside companies make its COVID-19 pill. “Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people. We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain…

Wall Street’s main indexes hit record highs in a broad-based rally on Friday as data showing strong jobs growth in October, coupled with Pfizer’s COVID-19 pill update, boosted sentiment about economic growth. Ten of the 11 major S&P sectors advanced in early trading, with economy-sensitive energy, financials, and industrials gaining more than 1 percent each….

Britain has become the first country to approve an antiviral COVID-19 treatment that can be taken as a pill at home. The UK national medicines regulator, the MHRA, announced on Nov. 4 that the antiviral Lagevrio (molnupiravir) had been authorised to treat mild to moderate COVID-19—in those with other risk factors, such as obesity, diabetes,…